<DOC>
	<DOC>NCT02540460</DOC>
	<brief_summary>The purpose of this study is to investigate the population pharmacokinetics of LCB01-0371 after a multiple oral dose in healthy male subjects. To investigate safety, tolerability of LCB01-0371 after a multiple oral dose in healthy male subjects.</brief_summary>
	<brief_title>Multiple Ascending Dose, Phase 1 Clinical Study of LCB01-0371</brief_title>
	<detailed_description>Double blind, randomized, placebo control, multiple dose, dose escalation study</detailed_description>
	<criteria>1. Healthy male between 20 and 45 years of age at the time of screening 2. Subjects with body mass index (BMI) between 20 kg/m2 and 27 kg/m2 at the time of screening 3. Agree to continue to use a medically reliable dual contraception and not to donate sperm until 30th days after study completion 4. Capable of giving written informed consent, willing to participate in this clinical trial, and willing to comply with all study requirements. 1. History of liver, kidney, alimentary, respiratory, musculoskeletal, endocrine, neuropsychiatric, hematooncologic, cardiovascular problem(s) 2. History of gastrointestinal problem (e.g. Crohn's disease, gastrointestinal ulcer) within 6 months possibly affecting absorption of clinical trial drugs, or history of surgery (except simple appendectomy and herniotomy) 3. History of hypersensitivity reaction or history of clinically significant hypersensitivity reaction to LCB010371 or same class of the study drugs (linezolid) or other drugs including aspirin and antibiotics 4. History of drug abuse or positive result at urine drug screening 5. AST, ALT, rGT, bilirubin(total) values over than 1.5 times of ULN</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>